Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Can lipitor cause joint pain in everyoneHave you tried any alternatives to lipitorWhat are the risks of combining advil and ginkgo bilobaIs lipitor a substitute for stretchingHow does alcohol affect my health
Keytruda, a drug whose active ingredient is pembrolizumab, received its initial FDA approval for cancer treatment on September 4, 2014 [1][2]. The FDA approved Keytruda for the treatment of advanced melanoma in adults and children [1][2]. Keytruda works as a programmed death receptor-1 (PD-1) blocking antibody that helps the body's immune system attack cancer cells [1][2]. Since its initial approval, Keytruda has received additional approvals for treating other types of cancer [1]. References: [1] <https://www.drugpatentwatch.com/p/biologics/tradename/KEYTRUDA> [2] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679831/> [3] <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-first-line-treatment-head-and-neck-squamous-cell-carcinoma>
Follow-up: When did Keytruda first receive FDA approval for cancer treatment? What year was Keytruda initially approved by the FDA for cancer therapy? Can you tell me Keytruda's initial FDA approval date in cancer care?
DrugPatentWatch - Make Better Decisions © thinkBiotech LLC 2004 - 2024. All rights reserved.